Retatrutide is an innovative tri-agonist peptide engineered to engage GLP-1, GIP, and glucagon receptors simultaneously. This multi-receptor activation not only mimics the actions of conventional GLP-1 agonists, such as delayed gastric emptying and appetite suppression, but also uniquely boosts glucagon-mediated pathways that facilitate the breakdown of stored fats and glycogen, thereby enhancing basal metabolic rate for sustained fat oxidation.
Preclinical research is exploring Retatrutide’s potential to promote adipose tissue browning, improve glucose and lipid profiles, and support tissue repair while reducing inflammatory signals and modulating mitochondrial function. These multifaceted effects make it a valuable investigative tool for advancing our understanding of metabolic restoration, injury recovery, and the management of chronic inflammation.
Supplied under stringent analytical conditions to ensure high purity and structural integrity (via HPLC and MS), Retatrutide is intended solely for in vitro and in vivo research purposes.
For Research Use Only – Not for Human Consumption.